Sentences with phrase «in costimulatory»

Involved in the costimulatory signal essential for T - cell receptor (TCR)- mediated T - cell activation.

CpG stimulation of precursor B lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells towards a Th1 response.

Not exact matches

Thus, transport of peptide — MHC II complexes by DCs not only accomplishes transfer from late endocytic compartments to the plasma membrane, but does so in a manner that selectively concentrates TCR ligands and costimulatory molecules for T cell contact.

Insight into this mechanism led the researchers to design new peptides — snippets of the human B7 - 2 receptor protein — that powerfully block the binding of a superantigen to its costimulatory receptor targets, and thereby protect against lethal toxic shock, as they showed in animals.

Because previous work in rats and monkeys has found that proteins that block the costimulatory signal can hold T cells at bay, Kim Olthoff, a transplant surgeon at the University of Pennsylvania Medical Center in Philadelphia, thought her team could achieve a targeted immune suppression by getting the transplanted organ itself — rather than proteins injected into the bloodstream — to block the costimulatory signal.

Single - cell differential gene expression analysis revealed a spectrum of known transcripts, including several linked to cytotoxic and costimulatory function that are expressed at higher levels in the TEMRA (effector memory T cells expressing CD45RA) subset, which is highly enriched for CD4 - CTLs, compared with CD4 + T cells in the central memory (TCM) and effector memory (TEM) subsets.

The role of costimulatory signals in T cell induction was evaluated in mice lacking the interleukin - 2 (IL - 2) gene.

Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4 + T Cells.

Decreased expression of B7 costimulatory molecules and major histocompatibility complex class - I in human hepatocellular carcinoma.

Initial studies demonstrated that ligation of 4 - 1BB on T cells could deliver costimulatory signals resulting in either increased proliferation or enhanced cytokine secretion and also control clonal expansion and differentiation of effector and memory T cells.

Costimulatory B7 - H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

In 2002, his group was the first to report the design of «second - generation» CARs that, in addition to a binding domain outside of the T cell and a signaling domain inside, included a costimulatory domain designed to promote cell proliferation and survivaIn 2002, his group was the first to report the design of «second - generation» CARs that, in addition to a binding domain outside of the T cell and a signaling domain inside, included a costimulatory domain designed to promote cell proliferation and survivain addition to a binding domain outside of the T cell and a signaling domain inside, included a costimulatory domain designed to promote cell proliferation and survival.

These include T - cell depletion by apoptosis; anergy (ie, the process by which T cells that are presented with a peptide in the absence of costimulatory signals become refractory to further stimulation with the antigen and are therefore inactivated); and the development of regulatory T cells, which can actively suppress antigen - specific responses following re-challenge with the antigen.

Costimulatory molecule B7 - H1 in primary and metastatic clear cell renal cell carcinoma.

Functionally, T cells stimulated by antigen but without costimulatory signals, are able to proliferate and expand in numbers, but only transiently, with proliferation being very short - lived and few T cells being able to survive over time (Rogers, 1998, J Immunol).

Dr. Freeman's laboratory focuses on the identification and function of T cell costimulatory and coinhibitory pathways in regulating T cell activation and application of this knowledge to the development of more effective immunotherapies for cancer, infections, asthma, and autoimmune diseases.

We are currently investigating the role of various T - cell costimulatory pathways in regulating the humoral and cellular responses to and between DENV and ZIKV, and are defining the particular pathways that should be targeted to maximize safety and efficacy of vaccines.